title: Combining erythropoietin infusion with intramyocardial delivery of bone marrow cells is more effective for cardiac repair.
abstract: We postulated that combining erythropoietin (EPO) infusion with bone marrow mesenchymal stem cells (MSC) delivery may give better prognosis in a rat infarcted heart. Acute myocardial infarction (MI) model was developed by coronary artery ligation. Animals were grouped (n=18) to receive intramyocardial injection of 30 microl saline solution without cells (EPO and control groups) or with 3x10(6) MSC from transgenic green fluorescent protein (GFP)+ male mice (MSC and MSC-EPO groups). The animals received either 5000 U/kg body weight EPO (EPO and MSC-EPO groups) or saline solution (MSC and control groups) for 7 days after MI. Cardiac functions were measured by echocardiography and cardiac tissue was harvested for immunohistological studies 3 weeks after surgery. We observed regeneration of MSC in and around the infarcted myocardium in MSC and MSC-EPO groups. Capillary density was markedly enhanced with significantly smaller infarct size and reduced fibrotic area in MSC-EPO group as compared with other three groups. A smaller left ventricular (LV) diastolic dimension and a higher LV fractional shortening were observed in MSC-EPO group than in other three groups. Transplantation of MSC combined with cytokine EPO is superior to either of the monotherapy approach for angiomyogenesis and cardiac function recovery.
authors.affiliation: First affiliated hospital of Nanjing Medical university, Nanjing, China.
authors.forename: Dingguo
authors.initials: D
authors.lastname: Zhang
authors.forename: Fumin
authors.initials: F
authors.lastname: Zhang
authors.forename: Yuqing
authors.initials: Y
authors.lastname: Zhang
authors.forename: Xiang
authors.initials: X
authors.lastname: Gao
authors.forename: Chuanfu
authors.initials: C
authors.lastname: Li
authors.forename: Naiquan
authors.initials: N
authors.lastname: Yang
authors.forename: Kejiang
authors.initials: K
authors.lastname: Cao
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000379:methods*; D002196:Capillaries / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D004452:Echocardiography; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005355:Fibrosis / Q000473:pathology / Q000517:prevention & control; D015552:Injections, Intralesional; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D051379:Mice; D009203:Myocardial Infarction / Q000473:pathology / Q000628:therapy*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D004921:Erythropoietin